| Literature DB >> 35740134 |
Shoji Takenaka1, Maki Sotozono1, Naoto Ohkura1, Yuichiro Noiri1.
Abstract
Antimicrobial mouthwash improves supragingival biofilm control when used in conjunction with mechanical removal as part of an oral hygiene routine. Mouthwash is intended to suppress bacterial adhesion during biofilm formation processes and is not aimed at mature biofilms. The most common evidence-based effects of mouthwash on the subgingival biofilm include the inhibition of biofilm accumulation and its anti-gingivitis property, followed by its cariostatic activities. There has been no significant change in the strength of the evidence over the last decade. A strategy for biofilm control that relies on the elimination of bacteria may cause a variety of side effects. The exposure of mature oral biofilms to mouthwash is associated with several possible adverse reactions, such as the emergence of resistant strains, the effects of the residual structure, enhanced pathogenicity following retarded penetration, and ecological changes to the microbiota. These concerns require further elucidation. This review aims to reconfirm the intended effects of mouthwash on oral biofilm control by summarizing systematic reviews from the last decade and to discuss the limitations of mouthwash and potential adverse reactions to its use. In the future, the strategy for oral biofilm control may shift to reducing the biofilm by detaching it or modulating its quality, rather than eliminating it, to preserve the benefits of the normal resident oral microflora.Entities:
Keywords: adverse reaction; bacterial adhesion; cariostatic property; dental biofilm; gingivitis; microbiota; mouthwash
Year: 2022 PMID: 35740134 PMCID: PMC9219991 DOI: 10.3390/antibiotics11060727
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Oral biofilm and its niches.
Figure 2Biofilm formation and the therapeutic target for its control at each stage. The brown arrows indicate the channels that allow the transport of nutrients, waste products, and signaling molecules within the biofilm. The image is based on the process described by Costerton and Stewart in 2001 [38].
A summary of search terms and results in this study.
| Sequence No. | Terms and Strategy (Publication Dates from 2012 to 2022) | Hits |
|---|---|---|
| #1 | (“mouthwashes” [Pharmacological Action] OR “mouthwashes” [MeSH Terms] OR “mouthwashes” [All Fields] OR “mouthwash” [All Fields] OR “mouthwashing” [All Fields] OR “mouthwashings” [All Fields]) AND (“systematic review” [Publication Type] OR “systematic reviews as topic” [MeSH Terms] OR “systematic review” [All Fields]) | 300 |
| #2 | (“mouthwashes” [Pharmacological Action] OR “mouthwashes” [MeSH Terms] OR “mouthwashes” [All Fields] OR “mouthwash” [All Fields] OR “mouthwashing” [All Fields] OR “mouthwashings” [All Fields]) AND (“meta analysis” [Publication Type] OR “meta analysis as topic” [MeSH Terms] OR “meta analysis” [All Fields]) | 246 |
| #3 | (“mouthrinse” [All Fields] OR “mouthrinsed” [All Fields] OR “mouthrinses” [All Fields] OR “mouthrinsing” [All Fields] OR “mouthrinsings” [All Fields]) AND (“systematic review” [Publication Type] OR “systematic reviews as topic” [MeSH Terms] OR “systematic review” [All Fields]) | 57 |
| #4 | (“mouthrinse” [All Fields] OR “mouthrinsed” [All Fields] OR “mouthrinses” [All Fields] OR “mouthrinsing” [All Fields] OR “mouthrinsings” [All Fields]) AND (“meta analysis” [Publication Type] OR “meta analysis as topic” [MeSH Terms] OR “meta analysis” [All Fields]) | 40 |
Figure 3Flow diagram of the screening and selection process.
Summary of the reductions in plaque indices.
| Solutions |
| Weighted Mean Difference (95% Cl) | Index | Compared Control | Follow-up Periods | Reference |
|---|---|---|---|---|---|---|
| CHG | 12 | −1.45 (−1.00 to −1.90) | QHI | Baseline | 4 to 6 weeks | [ |
| 4 | −0.78 (−1.07 to −0.49) | TQHI | Placebo | 6 months | [ | |
| 3 | −0.640 (−0.756 to −0.524) | TQHI | Placebo | 6 months | [ | |
| 2 | −0.208 (−0.351 to −0.065) | PI | Placebo | 6 months | [ | |
| 17 | −0.362 (−0.571 to −0.153) † | QHI or TQHI | Baseline | ≥ 4 weeks | [ | |
| 5 | −0.39 (−0.70 to −0.08) | PI | Baseline | 6w or 6m | [ | |
| 10 | −0.67 (−0.82 to −0.52) | QHI | Baseline | 4w to 6m | [ | |
| EO | 9 | −0.86 (−1.05 to −0.68) | TQHI | Placebo | 6 months | [ |
| 9 | −0.827 (−1.053 to −0.600) | TQHI | Placebo | 6 months | [ | |
| 16 | −0.265 (−0.405 to −0.124) † | QHI or TQHI | Baseline | ≥ 4 weeks | [ | |
| 14 | −0.86 (−1.05 to −0.66) | QHI | Placebo | 6 months | [ | |
| 4 | −0.39 (−0.3 to −0.47) | QHI | 21.6 or 26.9% hydro-alcohol | 6 months | [ | |
| CPC (>0.05%) | 6 | −0.41 (−0.65 to −0.17) | TQHI | Placebo | 6 months | [ |
| 3 | −0.465 (−0.631 to −0.299) | TQHI | Placebo | 6 months | [ | |
| 8 | −0.112 (−0.273 to 0.029) *,† | TQHI | Baseline | ≥ 4 weeks | [ | |
| 9 | −0.70 (−0.83 to −0.57) | PI, TQHI, MPI | Placebo | ≥ 6 weeks | [ | |
| CPC (<0.05%) | 3 | −0.26 (0.07 to −0.55) * | TQHI | Placebo | 6 months | [ |
| Del | 2 | −0.24 (−0.67 to 0.19) * | TQHI | Placebo | 6 months | [ |
| 3 | −0.144 (−0.231 to −0.058) | TQHI | Placebo | 6 months | [ | |
| 4 | −0.173 (−0.853 to 0.507) *,† | TQHI | Baseline | 4 weeks | [ | |
| AmF/SnF | 2 | −0.079 (−0.260 to 0.101) * | TQHI | Placebo | 6 months | [ |
| 2 | −0.195 (−0.335 to −0.054) | PI | Placebo | 6 months | [ | |
| Alexi | 2 | −0.18 (−0.60 to 0.24) * | TQHI | Placebo | 6 months | [ |
| Tric | 3 | −0.67 (−1.05 to −0.30) | TQHI | Placebo | 6 months | [ |
| Herb | 6 | −2.93 (−6.43 to 0.58) * | PI or TQHI | CHG | 4 weeks | [ |
| 6 | 2.61 (4.42 to 0.9) | PI or TQHI | CHG or Placebo | 12 weeks | [ | |
| 11 | 0.22 (0.20 to 0.24) | PI or QHI or TQHI | CHG | [ | ||
| 5 | −0.61 (−0.80 to −0.42) | QHI | Placebo | 2w to 3 M | [ | |
| 5 | 0.08 (−0.19 to 0.34) * | PI | CHG | 10d to 3w | [ | |
| 5 | 0.00 (−0.04 to 0.04) * | TQHI | CHG | 2 or 4w | [ | |
| Curcumin | 6 | 0.27 (−0.53 to 1.07) * | PI or TQHI | CHG | 21 or 28 days | [ |
| Propolis | 3 | −1.24 (−2.51 to 0.04) * | PI | Placebo | 3 or 5 days | [ |
|
| 12 | −0.46 (−0.29 to −0.63) | PI or TQHI | Placebo | 4d to 2m | [ |
|
| 18 | 0.19 (0.01 to 0.37) * | PI or TQHI | CHG | 4d to 2m | [ |
| Green Tea | 5 | −0.14(−1.80 to 1.43) * | PI | CHG | 2 to 4w | [ |
| ClO2 | 5 | −0.720 (−0.487 to −0.952) | PI | Placebo | 7 days to 5w | [ |
n: number of studies, CHG: chlorhexidine gluconate mouthwash, EO: essential-oil-containing mouthwash (Listerine antiseptic), CPC: cetylpyridinium chloride mouthwash, Del: delmopinol mouthwash, AmF: amine fluoride mouthwash, SnF: stannous fluoride mouthwash, Alexi: alexidine, Tric: triclosan, PI: plaque index (Loe and Silness), QHI: Quigley-Hein plaque index, TQHI: Turesky modification of the Quigley-Hein plaque index, MPI: modified proximal index. † Expressed as the summary relative difference meaning a percentage change from the baseline. * No significant difference (p > 0.05).
Summary for the reduction of gingival indices.
| Solutions |
| Weighted Mean Difference (95% Cl) | Index | Compared Control | Follow-up Periods | Reference |
|---|---|---|---|---|---|---|
| CHG | 3 | −1.20 (−0.23 to −2.16) | GI or MGI | Placebo | 6 months | [ |
| 10 | −0.21 (−0.11 to −0.31) | GI | Baseline | 4 to 6 weeks | [ | |
| 4 | −0.185 (−0.285 to −0.086) | GI | Placebo | 6 months | [ | |
| 19 | −0.223 (−0.412 to −0.034) † | GI or MGI | Baseline | ≥ 4 weeks | [ | |
| 8 | −0.32 (−0.42 to −0.23) | GI | Baseline | 6w, 3m, 6m | [ | |
| EO | 9 | −1.44 (−0.82 to −2.06) | GI or MGI | Placebo | 6 months | [ |
| 2 | −0.133 (−0.194 to −0.072) | GI | Placebo | 6 months | [ | |
| 8 | −0.537 (−0.764 to −0.311) | MGI | Placebo | 6 months | [ | |
| 16 | −0.203 (−0.312 to −0.093) † | GI or MGI | Baseline | ≥ 4 weeks | [ | |
| 2 | −0.36 (−0.26 to −0.62) | GI | 21.6 or 26.9% hydro-alcohol | 6 months | [ | |
| 11 | −0.52 (−0.67 to −0.37) | MGI | Placebo | 6 months | [ | |
| 3 | −0.24 (−0.46 to −0.01) | GI | Placebo | 6 months | [ | |
| CPC (>0.05%) | 2 | −1.04 (0.06 to −2.14) * | GI or MGI | Placebo | 6 months | [ |
| 5 | −0.70 (−0.83 to −0.57) | GI | Placebo | ≥ 6 weeks | [ | |
| 3 | −0.344 (−0.627 to −0.062) | GI | Placebo | 6 months | [ | |
| 2 | −0.357 (−0.483 to −0.231) | MGI | Placebo | 6 months | [ | |
| 8 | −0.126 (−0.312 to 0.059) *,† | GI or MGI | Baseline | ≥ 4 weeks | [ | |
| CPC (≤0.05%) | 3 | −0.31 (0.76 to −1.38) * | GI or MGI | Placebo | 6 months | [ |
| Del | 1 | −0.06 (1.86 to −1.98) * | GI or MGI | Placebo | 6 months | [ |
| 2 | −0.038 (−0.145 to −0.069) * | MGI | Placebo | 6 months | [ | |
| 3 | −0.014 (−2.337 to 2.308) †,* | GI or MGI | Baseline | ≥ 4 weeks | [ | |
| AmF/SnF | 1 | −0.76 (0.72 to −2.25) * | GI or MGI | Placebo | 6 months | [ |
| 2 | −0.248 (−0.427 to −0.069) | GI | Placebo | 6 months | [ | |
| Alexi | 1 | −0.16 (1.77 to −2.09) * | GI or MGI | Placebo | 6 months | [ |
| Tric | 3 | −1.50 (−0.36 to −2.62) | GI or MGI | Placebo | 6 months | [ |
| Herb | 6 | −0.15 (−0.32 to 0.01) * | GI | CHG | 4 weeks | [ |
| 5 | −0.09 (−0.25 to 0.08) * | GI | CHG | 12 weeks | [ | |
| 3 | −0.28 (−0.51 to −0.06) | GI | Placebo | 3 w or 3 m | [ | |
| 3 | −0.59 (−1.08 to −0.11) | MGI | Placebo | 2 to 4 weeks | [ | |
| 5 | −0.07 (−0.22 to 0.07) * | GI | CHG | 2 to 4 w | [ | |
| Curcumin | 6 | −0.13 (−0.35 to 0.09) * | GI | CHG | 21 or 28 days | [ |
| Green Tea | 5 | 0.43(−0.63 to 1.49) * | GI | CHG | 2 to 4 w | [ |
| ClO2 | 4 | −0.712 (−0.457 to −0.967) | GI | Placebo | 7 to 21 days | [ |
n: number of studies, CHG: chlorhexidine gluconate, EO: essential oils (Listerine antiseptic), CPC: cetylpyridinium chloride. Del: delmopinol, AmF/SnF: amine fluoride/stannous fluoride, Alexi: alexidine, Tric: triclosan, GI: gingival index (Löe and Silness), MGI: modified gingival index. † Expressed as the summary relative difference, meaning a percentage change from the baseline. * There was no significant difference (p > 0.05).
A summary of representative experiments demonstrating that sub-minimum inhibitory concentration of antimicrobial agents upregulated pathogenic genes.
| Biocide | Concentration | Species | Condition of Bacteria | Incubation Time | Upregulated Genes | Reference |
|---|---|---|---|---|---|---|
| NaF, CHG, | 1/2 MIC |
| Planktonic | 24 h |
| [ |
| NaF, CHG, | 1/2 MIC |
| Biofilm | 24 h |
| [ |
| Triclosan | 1/2 and |
| Planktonic | 2 h |
| [ |
| MTAD, MTADN, MTAN | 1/4 MIC |
| Planktonic | 1 h | [ | |
| CHG | 1/10 MIC | Biofilm | 48 h |
| [ |
MTAD: 3% doxycycline, 4.5% citric acid, and 0.5% polysorbate 80 detergent. MTADN: nisin combined with MTAD. MTAN: nisin in place of doxycycline in MTAD.
Figure 4Schematic diagram of the clinical effects of mouthwashes against supragingival dental biofilm with strong evidence. The anti-biofilm property (1) has been proven to be effective, followed by the anti-gingivitis property (2), and their cariostatic actions are aimed at children and adolescents (3). There are no conclusive findings regarding the preventive effect of fluoride mouthwash alone on root caries.
Figure 5Posible adverse reactions inside the mature oral biofilm. Exposure of a mature oral biofilm to mouthwash is associated with several possible adverse reactions, such as the emergence of a resistant strain, effects of the residual structure, enhanced pathogenicity following retarded penetration, and ecological changes to the microbiota.